Expression of c-Myc and p53 Correlates With Clinical Outcome in Diffuse Large B-Cell Lymphomas
Open Access
- 1 April 2000
- journal article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 113 (4), 512-518
- https://doi.org/10.1309/yhfe-r65b-d3lk-3ggv
Abstract
We performed a retrospective immunohistochemical study of the relationships between clinical manifestations and outcomes of diffuse large B-cell lymphoma (DLBCL) and expression of oncogenic proteins in 21 cases of DLBCL at various clinical stages. Cases of nodal origin expressed p53 more often and presented with high clinical stage more frequently than those of extranodal origin. Expression of c-Myc or p53, but not Bcl-6, Bcl-2, or Bcl-1, showed a statistically significant positive correlation with high clinical stage at presentation and with high or high-intermediate risk. Coexpression of c-Myc and p53 occurred in 7 of 12 patients with high clinical stage but was absent in patients with low clinical stage; coexpression was more frequent in patients with high or high-intermediate risk than in patients with low or low-intermediate risk. Four patients with this coexpression pattern demonstrated an unusually aggressive clinical course (median survival, 7 months). Coexpression of c-Myc and p53 seems to be a better indicator than the MIB1 proliferative index for identification of a cohort of aggressive disease in patients with DLBCL.Keywords
This publication has 23 references indexed in Scilit:
- Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins.Journal of Clinical Oncology, 1998
- Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: Clinical relevance in 71 patientsAnnals of Oncology, 1998
- Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study.Journal of Clinical Oncology, 1996
- Rearrangement of the bcl-6 Gene as a Prognostic Marker in Diffuse Large-Cell LymphomaThe New England Journal of Medicine, 1994
- Identification of genetic lesions associated with diffuse large-cell lymphomaAnnals of Oncology, 1994
- Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases.Journal of Clinical Oncology, 1994
- bcl-2 Rearrangements in de novo diffuse large cell lymphoma. Association with distinctive clinical featuresCancer, 1993
- The Association of c-myc Rearrangements with Specific Types of Human Non-Hodgkin's LymphomasLeukemia & Lymphoma, 1992
- 18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significanceBritish Journal of Haematology, 1989
- bcl-2 and Other Genomic Alterations in the Prognosis of Large-Cell LymphomaThe New England Journal of Medicine, 1989